T Cell Lymphomas
Commentary
New Drug Approvals Are the Wrong Metric for Cancer Policy
How should we define success in cancer policy — what should the endpoint be?
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.
From the Journals
Consider These Factors in an Academic Radiation Oncology Position
Editorial gives guidance to radiation oncologists seeking academic positions.
Feature
Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
A snapshot assessment of metabolic syndrome is inadequate to show an association with cancer risk over time, the authors of new research say.
Feature
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
But some radiation oncologists do not agree with the proposal to move back to direct in-person supervision only.
Feature
Are Food Emulsifiers Associated With Increased Cancer Risk?
Food emulsifiers are among the most widespread food additives.
Feature
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
The company, which said in May that it was working to assuage critical shortages of methotrexate, carboplatin and cisplatin, is being asked to...
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
Feature
CAR T-Cell: Do Benefits Still Outweigh Risks?
“Cautious reassurance” urged, as early reports suggest that the risks of secondary malignancies are similar to those of other cancer treatments....
Conference Coverage
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?
New research suggests that CAR T-cell therapy might prove to be a game-changing treatment for lupus and two other autoimmune diseases.
News
FDA OKs new agent to block chemotherapy-induced neutropenia
Efbemalenograstim has been approved by the FDA to combat infections in adults being treated for nonmyeloid cancers.